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Summary 
The TARGIT-A trial found no significant difference between TARGIT-IORT and EBRT in 
terms of local recurrence of breast cancer or breast cancer survival. In this longitudinal 
single-site TARGIT-A sub-study, TARGIT-IORT had similar cosmetic outcomes to EBRT 
but better breast-related quality of life, as reported by patients. This was despite this analysis 
being limited to patients who had received TARGIT-IORT as a separate procedure by re-
opening the wound (post-pathology). 
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Abstract 
Purpose: 
The international randomized TARGIT-A trial compared risk-adapted single-dose intra-operative 
radiotherapy (TARGIT-IORT) to 3-7 weeks of daily conventional external beam radiotherapy 
(EBRT) in women with early breast cancer treatable with breast conserving surgery. TARGIT-A 
showed TARGIT-IORT to be non-inferior compared to EBRT in terms of reducing the risk of local 
cancer recurrence and found no difference in breast cancer survival however its effect on patient 
reported cosmesis and breast-related quality of life (QOL) have not yet been described. 
Methods and Materials: 
Longitudinal cosmesis and QOL data were collected from a sub-set of TARGIT-A participants who 
received TARGIT-IORT as a separate procedure (post-pathology). Patients completed a cosmetic 
assessment before radiotherapy and annually thereafter for at least five years. Patients also 
completed the combined EORTC core questionnaire (QLQ-C30) and Breast Specific Module 
(BR23) in addition to the Body Image after Breast Cancer Questionnaire (BIABC) at baseline and 
annually thereafter. The combined EORTC questionnaires were also collected 3, 6, and 9 months 
after wide local excision (WLE). 
Results: 
An Excellent-Good (EG) cosmetic result was scored more often than a Fair-Poor (FP) result for 
both treatment groups across all time points. TARGIT-IORT patients reported better breast-related 
QOL than EBRT patients. Statistically and clinically significant differences were seen at month-6 
and Year-1, with EBRT patients having moderately worse breast symptoms (a statistically 
significant difference of more than 10 in a 100 point scale) than TARGIT-IORT patients at these 
time points. 
Conclusion: 
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Patients treated with TARGIT-IORT on the TARGIT-A trial have similar self-reported cosmetic 
outcome but better breast-related QOL outcomes than patients treated with EBRT. This important 
evidence can facilitate the treatment decision making process for patients who have early breast 
cancer suitable for breast conserving surgery and inform their clinicians. 
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Introduction 
Whole breast external beam radiotherapy (EBRT) delivered in 15-35 daily fractions over 3-7 weeks 
is standard adjuvant treatment for women undergoing breast conserving surgery for early breast 
cancer1,2. EBRT may require temporary relocation for women who are geographically isolated or 
unable to travel daily3. EBRT can have acute toxicities such as erythema, oedema, breast induration 
and skin breakdown4 and  long-term toxicities including local pain, fibrosis, telangiectasia and 
cosmetic changes4,5. Around 1-2% may develop pneumonitis, pulmonary fibrosis, cardiotoxicity, 
osteoradionecrosis, or secondary malignancies4,6,7. Some women choose to forego radiotherapy due 
to the inconvenience or potential toxicities, either accepting increased recurrence risks or choosing 
mastectomy8-10. 
Targeted Intra-Operative Radiotherapy (TARGIT-IORT) allows delivery of radiation directly to 
tissues at the site of the primary tumour in a single session at the time of wide local excision (WLE) 
or shortly afterwards. The TARGIT-A trial compared TARGIT-IORT to conventional EBRT. Five 
year results found TARGIT-IORT to be non-inferior to EBRT in terms of risk of local recurrence 
when delivered during WLE (pre-pathology) (non-inferiority could not be established for post-
pathology, but the difference was not statistically significant) and there was no difference in breast-
cancer survival11. Toxicities were low; TARGIT-IORT had significantly fewer skin toxicities (0.5% 
vs. 2%) but higher risk of post-operative seromas (2% vs. 0.8%)12. Cosmesis analysis utilising 
digital photographs showed better outcomes with TARGIT-IORT in the first year13. 
TARGIT-IORT is now considered an acceptable treatment option in several countries with delivery 
during WLE (pre-pathology) being the preferred approach. Awareness of cosmesis and QOL 
outcomes is paramount when clinicians are discussing treatment options with patients, in particular 
when comparing treatments with similar efficacy and survival. This sub-study is the first 
comprehensive investigation of patient reported cosmesis and breast-related QOL outcomes 
comparing patients randomised to TARGIT-IORT vs. EBRT on the TARGIT-A trial. 
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Patients and Methods 
Patients and Treatment 
Between 2000 and 2012 TARGIT-A registered 3451 patients from 33 centres in 11 countries. 
Patients with early breast cancer suitable for breast conserving surgery were randomized to receive 
either a single dose of TARGIT-IORT (50kV X-rays with INTRABEAM(TM) Carl Zeiss, 
Oberkochen Germany) or conventional 3-7 weeks EBRT. TARGIT-IORT patients with 
unfavourable pathology also received EBRT in ~15% of cases however these were excluded from 
this analysis. 
This sub-study includes 126 patients from three treatment centres in Western Australia.  Relevant 
ethics approvals were obtained and all participants provided written informed consent. 
TARGIT-IORT dose to 1cm was 5-6Gy (16-33Gy at applicator surface) and EBRT was 
conventional 3D conformal radiotherapy - (45-50.4Gy in 25-28 fractions). 
Eligibility for Australian patients randomized to the post-pathology stratification was stricter than 
the main trial; unifocal invasive ductal (not lobular) <2cm tumours, node negative, hormone 
positive, limited DCIS and lymphovascular negative disease. Fourteen EBRT and 4 IORT patients 
in this analysis were randomised pre-pathology where these criteria did not apply hence some 
deviations are shown in Table 1. 
Instruments and evaluations 
Patients were routinely assessed at baseline, i.e., after initial surgery, but before receiving either 
TARGIT-IORT (as a separate procedure) or EBRT, and annually thereafter for five years using the 
instruments given below: 
Cosmesis 
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The Global Harris Scoring System of Excellent, Good, Fair or Poor was used14-16. Responses are 
dichotomized into Excellent and Good (EG) or Fair and Poor (FP) categories (Table e1 
www.redjournal.org). Harris Scores were also completed by a Radiation Oncologist, Nurse and an 
objective photographic measurement system (BCCT.core), however these data will be reported 
separately. 
Quality of Life 
The European Organisation for Research and Treatment of Cancer (EORTC) core quality of life 
questionnaire (QLQ-C30), Breast Specific Module (BR23), and the Body Image after Breast Cancer 
Questionnaire (BIABC) were used. EORTC questionnaires were also collected 3, 6 and 9 months 
after WLE. These tools were chosen due to their reliability, validity and ongoing use in several 
international breast cancer trials17-21. 
The EORTC QLQ-C30 comprises five functional scales (Physical, Role, Emotional, Cognitive, 
Social), three symptom scales (Fatigue, Nausea/Vomiting, Pain), six single-item scales and a Global 
QOL scale18,22. The validated EORTC QLQ-BR23 has 23 questions grouped into five domains 
(Systemic Treatment Side Effects, Arm Symptoms, Breast Symptoms, Body Image, Sexual 
Functioning) and 3 single item domains for Sexual Enjoyment, Hair Loss, and Future 
Perspectives18,22,23. 
EORTC questionnaires were scored according to guidelines resulting in scores ranging from 0 to 
100. A high score signifies better functioning for functional domains but poorer scores for symptom 
domains18. The focus of this analysis is on the BR23 module. Most questions relate to patient 
experience in the last week, except for sexual functioning which has a four-week time frame. 
The BIABC is comprised of 6 domains: Vulnerability, Body Stigma, Limitations, Body Concerns, 
Transparency and Arm Concerns. Scoring was in accordance with the corrected scoring system24. 
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Higher scores signify worse functioning across all domains. Each domain has a different range of 
possible scores20,24,25. All questions relate to patient experience in the last four weeks. 
Panel Review of quality of life domains 
To reduce multiple testing and investigate only relevant breast-related domains, we performed a 
hypothesis-generating panel review of the two breast-specific questionnaires (BR23 and BIABC). 
The review was exploratory; we wished to hypothesise which domains might show differences 
between patients having TARGIT-IORT vs. EBRT. 
Ten health professionals from radiation and medical oncology, surgery, nursing and clinical trials 
who were familiar with TARGIT-IORT and EBRT participated. A domain was included in the 
analysis if it was scored as relevant by at least 3 responders. Four domains were identified from the 
BIABC questionnaire and the range of possible scores were: Arm Concerns-as it includes a question 
about breast-pain (5-25), Body Concerns (6-30), Body Stigma (15-75), and Transparency 
(obviousness of cancer to others and concern about cancer related appearance) (5-25); Four 
domains were identified from the BR23 questionnaire: Body Image, Breast Symptoms, Sexual 
Function and Sexual Enjoyment. 
Analysis and Interpretation 
Despite the panel review reducing the number of evaluable QOL domains from 26 to 8, a large 
number of tests were still required for the primary analysis. Statistical significance was therefore set 
at  p<0.01 to account for multiple comparisons22,26. 
Clinical significance utilizing the Osoba method is discussed according to QOL reporting 
guidelines22,27,28. A difference of at least 10 points on a 100 point scale is considered a minimal 
clinically meaningful change; a difference between 10 and 20 points is considered a moderate 
effect; and differences over 20 are considered a large effect22,29. 
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Sensitivity analyses were performed to investigate robustness of the complete case data. The 
EORTC scoring system allows domain scores to be calculated in two ways; a) only when all 
questions in that domain have been answered (complete case analysis) and b) when at least half of 
the questions in the domain have been answered, allowing the calculation of an average score for 
the domain (single imputation with mean substitution)18. Multiple imputation of missing data was 
also applied to both questionnaires18,30-32. Given the similarities in outcomes across the three 
datasets, only the findings from the complete case analysis are reported. 
IBM-SPSS V22 (SPSS Inc,.Chicago, IL) was used for: scoring QOL questionnaires; non-parametric 
analysis (Mann-Whitney-U and Chi2) of raw unadjusted data and for multiple imputation and single 
imputation for the sensitivity analyses. Generalized estimating equations (GEE) with a variable 
covariance structure were used for the longitudinal dichotomized cosmesis endpoint and linear 
mixed models were used for the continuous longitudinal QOL endpoints using SAS V9.3 (SAS 
Institute, Cary, NC). 
Results 
Of 385 Western Australian TARGIT-A patients, only the first 152 consecutive patients were invited 
to participate in this sub-study due to resource constraints, with 6 declining participation. A further 
20 were excluded due to confounders which would render cosmesis data uninterpretable, including 
a) received both TARGIT-IORT and EBRT (n=9), b) received TARGIT-IORT during WLE (n=1), 
c) no radiotherapy given (n=2) or d) history of contralateral disease (n=8). This left 126 evaluable 
participants, of whom 60 had TARGIT-IORT and 66 had EBRT (Figure 1). 
Participants and Compliance 
Compliance was very good and nearly identical across both treatment groups however as expected 
in a longitudinal study, compliance decreased over time (Table e2 www.redjournal.org).  Sensitive 
domains relating to sexual function had the worst compliance with a range of 21% to 81% missing 
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data across time points. There were no significant differences in baseline patient characteristics 
between treatment groups (Table 1). 
Cosmesis 
Despite a trend for greater proportions of TARGIT-IORT patients self-reporting an EG result 
compared to EBRT patients overall, multivariate longitudinal analysis did not reveal any 
statistically significant differences between treatment group at any time point (Figure 1). Models to 
test whether other factors (such as age, body mass index ,specimen size, EBRT boost and additional 
surgery) may have an impact revealed no other drivers of self-reported cosmetic outcome33. 
Univariate analysis revealed TARGIT-IORT patients had better cosmetic outcome compared to 
EBRT patients at Year-5 with 90% and 68.4% scoring EG respectively (p=0.007) (Figure 2). 
 
Quality of life results 
Mean baseline scores for the 8 QOL domains selected a-priori did not demonstrate any significant 
differences at the p<0.01 level between the two treatment groups (Table e3 www.redjournal.org). 
Exploratory analysis of Global QOL scores showed significantly better scores for TARGIT-IORT 
patients at baseline (79.5 TARGIT-IORT, 70.3 EBRT p=0.007).  
Beyond baseline, TARGIT-IORT patients tended to fare better than EBRT patients in terms of 
breast-related QOL. Non-parametric testing revealed statistically significantly better results 
consistently favoring the TARGIT-IORT group in the Arm Concerns domain at Year-1 (p<0.0001) 
(Table e4 www.redjournal.org), and Months 6 and 9 and Years 1, 3 and 4 (p<0.001) of the Breast 
Symptoms domain. A number of differences were also considered clinically significant (Table 2). 
Treatment (and its interaction with time) had a statistically and clinically significant impact on the 
Breast Symptoms (p=0.006) and Arm Concerns (p=0.005) domains, both favouring TARGIT-IORT 
(Table 3). Age was also found to be a significant factor in the Body Image (p=0.004) and Sexual 
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Function (p<0.001) domains where an increase in age was associated with worse body image and 
sexual function.  Time since treatment was found to impact the Sexual Function domain with lower 
scores seen at the Year-5 time point for both treatment groups (p=0.008). The Sexual Enjoyment 
domain shows mixed results suggesting an interaction between treatment and time (p<0.001) with 
TARGIT-IORT patients scoring worse function from BL to 6 months, then better function from 9 
months onwards with clinically significant differences at Years 1, 3 and 4. Age adjusted mean 
scores for QOL domains are illustrated in Figure 2 with further details shown in Table e5 
www.redjournal.org. 
Although the core EORTC questionnaire was not used in the a-priori analysis, we explored the 
Global QOL domain, which contains two questions relating to overall health and overall quality of 
life respectively. A higher score denotes better global QOL and results revealed TARGIT-IORT 
patients consistently scored higher scores than EBRT patients with statistically significant 
differences found at baseline, 3 and 6 months and 1 year. Clinically significant differences were 
seen at  3 and 6 months  (moderate and minimal clinical significance respectively) (Figure e1 
www.redjournal.org). 
Sensitivity Analyses 
All three approaches to analysis (complete case, single imputation, multiple imputation) produced 
similar parameter estimates and p-values. Minor disagreement was seen in two domains of the 
BIABC questionnaire at the p<0.05 level, but no differences were seen at the p<0.001 level. 
Specimen size was significant (p=0.035) in the complete case analysis of body stigma but 
insignificant in the MI analysis (p=0.064). The treatment vs. time interaction of the arm concerns 
domain was significant for the complete case analysis (p=0.006) but insignificant in the MI analysis 
(p=0.112). 
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The effect of missing data on the Year-5 cosmesis scores was tested by carrying forward the 
previous years’ result. This increased the proportion of an EG score from 68.4% to 69% for the 
EBRT group and decreased the proportion from 90% to 88% in the TARGIT-IORT. 
Discussion of results 
Intra-operative radiotherapy is a new way to offer adjuvant breast radiotherapy and few studies of 
cosmesis and QOL have been reported34-37. This TARGIT-A sub-study provides comprehensive 
patient-reported results comparing post-pathology TARGIT-IORT to EBRT. TARGIT-IORT was 
found to significantly impact breast symptoms, improving quality of life.  
TARGIT-IORT patients tended to self-report better outcomes for both cosmesis and QOL, such that 
a higher number scored an EG cosmetic result across all time points, and they experienced fewer 
symptoms and better functioning in breast-related QOL.  
The only significant difference in cosmesis was at Year-5 (EG scores were 68.4%-EBRT and 90%-
TARGIT-IORT, p=0.007, which coincidentally were the lowest and highest scores reported by 
patients across all time points). Study attrition as a potential cause of this difference was ruled out 
by sensitivity analysis. Overall, the proportion of patients scoring themselves as EG was high, and 
compares well to previous research which has shown that 70-80% of EBRT patients can expect an  
EG cosmetic outcome4. 
Clinically and statistically significant findings were seen at Year-1 for Arm Concerns and Month-6 
for Breast Symptoms. At these time points, EBRT patients experienced moderately higher levels of 
treatment-related symptoms, including breast and arm pain, swelling, oversensitivity and skin 
problems. These findings are in keeping with the results obtained from cross-sectional studies of 
QOL in TARGIT-A patients in Germany (median follow-up 47 months; pre-pathology patients)35,37 
and toxicity results from TARGIT-A12. 
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The increase in self-reported breast symptoms in EBRT patients observed 6-months post-WLE 
which subsided by the 9th month, was most likely because patients had only just finished their 
EBRT around this time, when waiting times were on average 4.5 months (2.3-7.9 months) for 
completion of EBRT. TARGIT-IORT patients had completed their treatment between 4 days and 4 
months after WLE, with the average completion time of 1.6 months. Given the lack of significant 
difference between breast symptoms reported at 3-months, TARGIT-IORT patients had presumably 
recovered from their procedure by the time the 3-month questionnaire was administered, when 
EBRT patients were just starting radiotherapy. By 6-months, TARGIT-IORT patients had improved 
further in terms of breast side effects, but EBRT patients who had recently ceased or were still 
receiving treatment, were experiencing the peak of treatment-related side effects. By 9-months both 
treatment groups scored better than baseline scores, which is in keeping with other longitudinal 
International QOL studies of EBRT21,38. 
Breast symptoms for both groups continued to reduce over time, showing better results for both 
groups at 4 years (4.2 for TARGIT-IORT and 9.9 for EBRT) when compared to the German Cohort 
(8.6 for TARGIT-IORT and 19.2 for EBRT)37. A similar reduction in breast symptoms over time 
was also seen in the START-A and B trials which assessed breast symptoms for different regimens 
of EBRT from baseline to Year 5 and also QOL studies performed in Australia/New Zealand and 
Canada which assessed both short and long term QOL post EBRT 21,38,39. 
In comparison to the 50Gy EBRT arm of the START trials, patients treated with TARGIT-IORT in 
the present study reported fewer breast symptoms at months 6 and years 1 and 5, however the 
patients treated with EBRT in the present study showed worse breast symptoms across all follow-up 
time points compared to TARGIT-IORT39,40. 
Overall, patients treated with TARGIT-IORT reported better global QOL scores at every time point. 
Despite not reaching clinical significance, it is worth noting that TARGIT-IORT patients scored 
better global QOL at baseline (79.5) compared to the EBRT group (70.3, p=0.007) who had a 
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similar score to the baseline scores for the 50Gy EBRT group in the START trials (69.8)40. The 
administration of the baseline questionnaire in the present study was performed after patients were 
randomised. We may hypothesise that either patients randomised to the TARGIT-IORT arm were 
actually experiencing better QOL, or that simply being randomised to the single treatment may have 
had a positive effect on their sense of wellbeing which improved  reported QOL. Anecdotally, 
patients randomised to TARGIT-IORT were visibly relieved to not have to endure the 6 week 
burden of EBRT, and patients randomised to EBRT would often become visibly upset when 
informed they drew the conventional arm (particularly those who would need to relocate to the city 
for the duration of their treatment, leaving behind dependents, animals, or other responsibilities). 
Statistically and clinically significant differences seen between TARGIT-IORT and EBRT at 3 and 
6 months suggests the impact of undergoing extended treatment  was reflected in global QOL 
scores of EBRT patients. The administration of the 3-month BR23 generally coincided with the 
start of EBRT (the median time to start EBRT was 7.5 days prior to 3-month BR23). This may have 
contributed to the poorer global QOL scores in the EBRT group. Patients who received TARGIT-
IORT completed the 3-month BR23 a median of 47 days after treatment, hence they may have 
returned to their usual routine by that time. 
Sensitivity analyses comparing complete case, single imputation and multiple imputation datasets 
produced similar outcomes. This similarity can be explained by excellent completion rates and 
generally good health exhibited by participants which led to few occasions where imputation was 
required. Multiple imputation is complex and time consuming and is not necessary with the amount, 
type and pattern of missingness experienced by this dataset. 
This analysis reports the experience of patients who received TARGIT-IORT as a separate 
procedure after WLE (post-pathology). Internationally, TARGIT-IORT during WLE (pre-
pathology) is now the preferred approach and we would not anticipate that the concurrent procedure 
would result in worse cosmetic or QOL outcomes.  As it is reasonable to expect that cosmetic 
outcome and quality of life would be worse in patients who have an additional procedure after 
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WLE, this is a factor that would work against finding better outcomes with TARGIT-IORT vs. 
EBRT in this study. Therefore, our findings of equal or better outcomes in such patients are even 
more significant. 
Limitations and Strengths 
This sub-study describes only a sub-set of TARGIT-A patients with a mix of patients from the pre 
and post-pathology stratifications. Sensitivity analysis showed missing data did not affect study 
outcomes, with the exception of sensitive questions relating to sexual function and intimacy in 
which missing data are universal18,41. On average, across each time point, 53% and 45% of 
TARGIT-IORT and EBRT patients respectively were sexually active, hence only half of the 
surveyed population could offer a score for the Sexual Enjoyment domain (on average 19 patients 
per group per time point). Such small numbers may reduce the generalisability of the reported 
findings for this domain despite excellent compliance rates. Furthermore, this study did not 
distinguish between partnered and non-partnered women, and information on adjuvant hormonal 
therapy was not reviewed, hence making it impossible to interpret whether a reduction in sexual 
function was potentially related to by these factors. 
While the results of this study show TARGIT-IORT and EBRT patients have similar long-term 
outcomes, the main clinically significant differences were seen within the first year.. Collection of 
data at months 3, 6 and 9 post WLE which encompass the radiotherapy treatment time frame is 
therefore a strength of this study as other studies using a cross-sectional approach miss out on this 
valuable information. Consideration must be given to the timing of assessment to facilitate 
interpretation. In this study the significant date was WLE, however radiotherapy end date may have 
been easier to interpret. 
Conclusion 
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Patients treated with TARGIT-IORT in the TARGIT-A trial have better breast-related QOL 
outcomes than patients treated with EBRT despite receiving TARGIT-IORT as a separate procedure 
(post-pathology). EBRT patients experience worse breast-specific symptoms such as pain, swelling, 
oversensitivity and skin problems during or shortly after treatment. Cosmetic outcomes were similar 
overall, but TARGIT-IORT patients had better cosmetic outcomes than EBRT patients at 5 years. 
This evidence is important for clinicians and patients as it can facilitate the decision-making process 
regarding treatment options for early breast cancer treatable with breast conserving surgery, 
particularly due to the convenience of TARGIT-IORT which may better suit patient preferences for 
treatment. 
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Figure 1: CONSORT Diagram 
 
Figure 2: Proportion of patients self-reporting Excellent-Good Cosmesis 
 
Figure 3: Age-Adjusted Mean QOL Scores 
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Table 1: Baseline patient characteristics by treatment 
Patient, treatment and tumour TARGIT-IORT EBRT 
N (%) 60 (48%) 66 (52%) 
Age (mean years +/- SD) 
Range 
63 (+/- 8.2) 
50-83 
62 (+/- 7.4) 
50-80 
Baseline assessments prior to any surgery 1 (2%) 12 (18%) 
Baseline BMI (mean score +/- SD) 
Baseline BMI Group* (BMI Range) 
1 – Underweight (<18.5) 
2 – Normal (18.5-24.99) 
3 – Overweight (25-29.99) 
4 – Obese (30+) 
29 (+/- 5.5) 
 
0% 
30% 
30% 
40% 
30 (+/- 5.9) 
 
0% 
16% 
50% 
34% 
Mean Tumour Size (mm) 
   <11(mm) 
    11-20 (mm) 
    >21(mm) *** 
10 (+/- 4.2) 
62% 
38% 
- 
11 (+/- 5.0) 
52% 
46% 
1.5% 
Tumour Grade 
   1 
   2 
   3*** 
 
37 (62%) 
23 (38%) 
0 
 
38 (57%) 
27 (41%) 
1 (1.5%) 
Tumour Type 
   IDC 
   Mixed IDC/ILC*** 
 
59 (98%) 
1 (1.7%) 
 
64 (97%) 
2 (3%) 
Lesions 
   1 
   2*** 
 
60 (100%) 
0 
 
65 (98%) 
1 (1.5%) 
Extensive DCIS (>25% of tumour + inside and out of tumour)*** 0 4 (6.3%) 
ER+ve 
PR+ve 
ER and PR –ve*** 
60 (100%) 
44 (73%) 
0 
64 (97%) 
52 (79%) 
2 (3%) 
Positive Nodes*** 0 1 (1.5%) (1 node) 
Largest Specimen Length (mean -mm +/- SD) 
Range 
89 (+/- 37.2) 
25-205 
89 (+/- 38.4) 
40-267 
Extent of Axillary Surgery 
   Nil 
 
3 (5%) 
 
2 (3%) 
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    SLNBx 
   Clearance 
49 (82%) 
8 (13%) 
55 (83%) 
9 (14%) 
Further Surgery Required 
   SLNBx 
   Margins 
   Revision of Scar 
 
2 (3.3%) 
2 (3.3%) 
2 (3.3%) 
 
2 (3%) 
7 (11%) 
0 
Radiotherapy Dose Range (Gy) 
Fractions (range) 
Boost Given (20Gy in 10 fractions) 
Supraclavicular Treatment 
16-33** 
1 
N/A 
N/A 
45-50.4 
25 (25-28) 
11 (17%) 
1 (1.5%) 
Chemotherapy*** 0 1 (1.5%) 
Baseline Patient Harris (% Excellent-Good) 85 (+/- 0.36) 82 (+/- 0.39) 
Baseline BR-23 QoL Scores (Range of possible scores) (+/-SD)  
Body Image (0-100) † 93 (15.6) 93 (9.6) 
Breast Symptoms (0-100) † 20 (17.4) 21 (18.4) 
Sexual Function (0-100) †† 22 (21.1) 19 (20.1) 
Sexual Enjoyment (0-100) †† 49 (34.3) 52 (19.7) 
Baseline BIABC QoL Scores (Range of possible scores) (+/-SD) 
Arm Concerns (5-25) † 
 9 (2.5)  9 (2.9) 
Body Concerns (6-30) † 16 (4.3) 16 (4.4) 
Body Stigma (15-75) † 30 (8.4) 33 (7.6) 
Transparency (5-25) † 
 6 (2.7)  7 (2.2) 
SD: Standard Deviation.* BMI: Body Mass Index. Australian Government Department of Health. About Overweight 
and Obesity. Canberra, Australia 2009.**Dose to surface of applicator. ***Factors relevant only to the pre-pathology 
stratification. † Higher score denotes worse symptoms.  †† Higher score denotes better functioning. SLNBx: Sentinal 
Lymph Node Biopsy 
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Table 2: Statistically and Clinically Significant Differences in long term QOL between TARGIT-
IORT and EBRT 
Domain BL 3 
month 
6 
month 
9 
month 1 Year 
2 
Year 3 Year 4 Year 5 Year 
Body Image 0.2 0.5 0.2 0.4 0.3 0.3 0.1 0.8 0.5 
Breast 
Symptoms 0.6 0.2 
0.000** 
(12) 
0.001** 
(7.9) 
0.000** 
(10.4) 
0.01
0* 
(5.8) 
0.000** 
(8.5) 
0.001** 
(5.7) 
0.014* 
(6.2) 
Sexual 
Function 0.5 0.2 0.9 0.9 
0.5 
(18.8) 
0.3 
(15.8
) 
0.4 
(15.7) 
0.1 
(22.1) 
0.035* 
(11.3) 
Sexual 
Enjoyment 0.7 0.7 0.3 0.4 
0.013* 
(18.8) 
0.09
1* 
(15.8
) 
0.036* 
(15.7) 
0.028* 
(22.1) 0.6 
Arm Concerns 0.5 n/a n/a n/a  0.000** (12.7) 0.2 
0.031* 
(7.5) 0.2 0.4 
Body 
Concerns 1 n/a n/a n/a 0.9 0.7 0.9 0.4 0.9 
Body Stigma 0.05 n/a n/a n/a 0.5 0.2 0.2 0.3 0.2 
Transparency 0.5 n/a n/a n/a 0.3 1 0.1 0.6 0.1 
BL: Baseline.*significant at the 0.05 p-level, **significant at the 0.01 p-level (Mann-Whitney-U-Test). 
Values in parentheses are the Osoba clinical significance score. Note that Osoba clinical significance is 
reached with a difference >10 on a 100 point scale. All clinically and statistically significant differences 
favoured TARGIT-IORT. 
Table 3: Longitudinal Mixed Model Regression p-values, adjusted for age and time 
Domain Age Treatment Time Treatment*Time BMI Specimen Size (mm) 
Body Image 0.004** (0.28) 0.8 0.9 0.7 n/a n/a 
Breast 
Symptoms 0.2 
<0.001** 
(-1.48) <0.001** 0.006** n/a n/a 
Sexual 
Function 
< 
0.001** 
(-1.15) 
0.3 0.008** 0.9 0.027* (-3.05) n/a 
Sexual 
Enjoyment 0.05 0.5 0.3 <0.001** n/a n/a 
Arm Concerns 0.6 0.021* (-0.43) 0.002** 0.005** n/a n/a 
Body 
Concerns 0.6 0.6 0.4 0.8 n/a n/a 
Body Stigma 0.3 0.2 0.5 0.6 n/a 0.019* (0.038) 
Transparency 0.016* (-0.05) 0.6 0.4 0.4 n/a n/a 
BMI: Body Mass Index.*significant at the <0.05 level; **significant at the <0.01 level; values in 
parentheses are the parameter estimates of TARGIT-IORT vs. EBRT: for every one unit of the variable, the 
QOL domain increases or decreases by this value. All significant findings favoured the TARGIT-IORT 
group. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
